TALPHERA
Talphera is a specialty pharmaceutical company developing and commercializing therapies in medically supervised settings. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute postoperative pain in hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures.
TALPHERA
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.talphera.com
Total Employee:
11+
Status:
Active
Contact:
650-216-6500
Email Addresses:
[email protected]
Total Funding:
191.65 M USD
Technology used in webpage:
Domain Not Resolving IPv6
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-11-15 | Lowell Therapeutics | Lowell Therapeutics acquired by Talphera | N/A |
| 2020-03-16 | Tetraphase Pharmaceuticals | Tetraphase Pharmaceuticals acquired by Talphera | N/A |
Investors List
Nantahala Capital Management
Nantahala Capital Management investment in Post-IPO Equity - Talphera
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Talphera
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Talphera
Skyline Ventures
Skyline Ventures investment in Post-IPO Debt - Talphera
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-09-30 | Encycle Therapeutics | Talphera investment in Venture Round - Encycle Therapeutics | 2.85 M CAD |
Newest Events participated
Official Site Inspections
http://www.talphera.com Semrush global rank: 5 M Semrush visits lastest month: 1.66 K
- Host name: acelrx.tempurl.host
- IP address: 149.28.220.224
- Location: Matawan United States
- Latitude: 40.4652
- Longitude: -74.2307
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07747
More informations about "Talphera"
Investors - Talphera
Mar 31, 2025 Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market …See details»
Talphera, Inc. - AnnualReports.com
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in …See details»
Talphera - Crunchbase Company Profile & Funding
Talphera is a specialty pharmaceutical company developing and commercializing therapies in medically supervised settings. It offers NanoTab, a tablet for oral …See details»
Talphera Announces First Quarter 2025 Financial Results and …
3 days ago In March 2025, Talphera announced the agreement for a financing of up to $14.8 million, including two committed tranches upon achievement of 25% and 50% enrollment and …See details»
AcelRx Announces Rebranding With Name Change to …
Jan 9, 2024 Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release ...See details»
Talphera - VentureRadar
Talphera, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies designed for use in medically supervised settings. …See details»
Talphera - 2025 Company Profile, Funding & Competitors - Tracxn
Apr 21, 2025 Talphera is a public company based in San Mateo (United States), founded in 2005 by Pamela Palmer. It operates as a Developer of therapeutics for renal replacement …See details»
AcelRx becomes Talphera, adopting new name to reflect pain pivot
Jan 10, 2024 Talphera ended September with $13.4 million and warned investors it expected to “need additional capital to fund our planned operations” within 12 months of its filing.See details»
Raffi Asadorian - Talphera
Mr. Asadorian brings more than 30 years of finance, strategy, and corporate development experience to Talphera. Prior to joining Talphera in August 2017, he served as the Chief …See details»
SEC Filing | Talphera
TALPHERA, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 00444T209 (CUSIP Number) 03/31/2025 ... Citizenship or Place of Organization CAYMAN ISLANDS …See details»
Talphera Inc, TLPH:NMQ profile - FT.com - Financial Times
May 2, 2025 Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s …See details»
Q1 2025 Talphera Inc Earnings Call - Yahoo Finance Canada
3 days ago Welcome to the Talphera first-quarter 2025 financial results conference call. This call is being webcast live via the Events page of the Investors section of Talphera's website at …See details»
Talphera Announces First Quarter 2025 Financial Results and
In March 2025, Talphera announced the agreement for a financing of up to $14.8 million, including two committed tranches upon achievement of 25% and 50% enrollment and …See details»
Talphera Announces First Quarter 2025 Financial Results and …
3 days ago Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in …See details»
Stephen J. Hoffman, PhD, MD | TALPHERA
Dr. Hoffman has served as a director on the Talphera Board of Directors since February 2010. From December 2017 to October 2019, he served as Chief Executive Officer and Director of …See details»
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Jan 9, 2024 Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings. Talphera …See details»
Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic …
3 days ago Cash Operating Expenses: $2.9 million for Q1 2025, down from $4.2 million in Q1 2024. Excluding Non-Cash Stock-Based Compensation: $2.7 million for Q1 2025, compared to …See details»
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Jan 9, 2024 Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings. Talphera …See details»
Corporate Governance Guidelines - Talphera
Oct 30, 2019 Talphera Pharmaceuticals, Inc. Corporate Governance Guidelines. ... that they do or do not believe joining such organization would represent a conflict of interest, impact the …See details»
Mission, Vision & Core Values of Talphera – …
Oct 2, 2024 At Talphera, our mission, vision, and core values play a crucial role in shaping the success of our company. These guiding principles not only define who we are as an …See details»